Steven Cohen’s NRX Pharmaceuticals NRXP Stock Holding History

Steven Cohen’s Portfolio NRXP Stock Details NRXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-15,979	Closed	-$43.3K	–	4260
2025 Q4	$43.3K	Buy	+15,979	New	+$42.9K	﹤0.01%	3794

Other funds holding NRXP

BGI

B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

BFG

Bleakley Financial Group Fairfield, New Jersey $7.85B AUM 31.48% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Steven Cohen's NRXP Position: Q1 2026 in Review

Steven Cohen sold out of NRX Pharmaceuticals (NRXP) in Q1 2026, closing a stake of 15,979 shares — an estimated $43.3K sold.

Steven Cohen first reported a position in NRXP in Q4 2025 and held it in 1 quarter. The position peaked at $43.3K in Q4 2025. 33 funds tracked by Wall St. Rank hold NRXP as of Q1 2026.

Steven Cohen reported no remaining NRX Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Steven Cohen sold 15,979 NRX Pharmaceuticals shares in Q1 2026, an estimated $43.3K.
Steven Cohen first reported a position in NRX Pharmaceuticals in Q4 2025 and held it in 1 quarter.
Steven Cohen's NRX Pharmaceuticals position peaked at $43.3K in Q4 2025.
33 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.